New combo therapy shows promise for tough liver cancer
NCT ID NCT06537908
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two types of drugs (anti-PD-1/PD-L1 and anti-VEGF) in 50 adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink tumors or slow cancer growth. Participants will receive the drugs and be monitored for side effects and response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital Fudan university
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?